Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascale André

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
Clinical analysis of human natural killer cellsPascale André, Nicolas Anfossi
Medecine Sciences : M/S|January 7, 2020
[Natural killer cells: promising targets in cancer therapy]Stéphanie Cornen, Pascale André, Laurent Gauthier, et al.
Cellular & Molecular Immunology|March 27, 2019
Targeting natural killer cells in solid tumorsGuillaume Habif, Adeline Crinier, Pascale André, et al.
Cellular & Molecular Immunology|July 3, 2020
Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19Olivier Demaria, Julien Carvelli, Luciana Batista, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2009
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivoCaroline Sola, Pascale André, Céline Lemmers, et al.
Haematologica|January 2, 2016
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cellsLoredana Ruggeri, Elena Urbani, Pascale André, et al.
Clinical Immunology (Orlando, Fla.)|January 23, 2010
Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cellsCéline Cognet, Catherine Farnarier, Laurent Gauthier, et al.
Journal for Immunotherapy of Cancer|October 19, 2019
Monalizumab: inhibiting the novel immune checkpoint NKG2AThorbald van Hall, Pascale André, Amir Horowitz, et al.
Immunity|August 12, 2006
Human NK cell education by inhibitory receptors for MHC class INicolas Anfossi, Pascale André, Sophie Guia, et al.
Oncotarget|May 1, 2018
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignanciesNorbert Vey, Lionel Karlin, Sophie Sadot-Lebouvier, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|March 29, 2008
Clinical analysis of human natural killer cellsPascale André, Nicolas Anfossi
Medecine Sciences : M/S|January 7, 2020
[Natural killer cells: promising targets in cancer therapy]Stéphanie Cornen, Pascale André, Laurent Gauthier, et al.
Cellular & Molecular Immunology|March 27, 2019
Targeting natural killer cells in solid tumorsGuillaume Habif, Adeline Crinier, Pascale André, et al.
Cellular & Molecular Immunology|July 3, 2020
Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19Olivier Demaria, Julien Carvelli, Luciana Batista, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 30, 2009
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivoCaroline Sola, Pascale André, Céline Lemmers, et al.
Haematologica|January 2, 2016
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cellsLoredana Ruggeri, Elena Urbani, Pascale André, et al.
Clinical Immunology (Orlando, Fla.)|January 23, 2010
Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cellsCéline Cognet, Catherine Farnarier, Laurent Gauthier, et al.
Journal for Immunotherapy of Cancer|October 19, 2019
Monalizumab: inhibiting the novel immune checkpoint NKG2AThorbald van Hall, Pascale André, Amir Horowitz, et al.
Immunity|August 12, 2006
Human NK cell education by inhibitory receptors for MHC class INicolas Anfossi, Pascale André, Sophie Guia, et al.
Oncotarget|May 1, 2018
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignanciesNorbert Vey, Lionel Karlin, Sophie Sadot-Lebouvier, et al.
Pageof 3